Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2006

View Archived Issues

RF9: the first neuropeptide FF antagonist prevents opioid tolerance

ChemGenex and Merck KGaA sign new three-year alliance agreement

Series A financing at CoLucid Pharmaceuticals

ImmuneRegen BioSciences submits proposal to Department of Defense

Targeting cannabinoid CB2 for bone protection

PPARgamma activation suppresses BACE1 to reduce AD pathophysiology

BioLineRx inlicenses new compounds, updates pipeline progress

Positive toxicology data for Binoxan active ingredient

AlphaVax and Wyeth enhance partnership

Ligand and Organon terminate Avinza copromotion

Boehringer Ingelheim launches RE-VOLUTION program for dabigatran etexilate

IND submission for clinical trials of Myodur in Duchenne muscular dystrophy

New German study evaluates AM-111 in acute sensorineural hearing loss

sanofi-aventis transfers Exubera rights to Pfizer

FDA requests pediatric studies of zolpidem

New Aphios subsidiary to develop antiinfluenza drugs from marine microorganisms

Caprion and Icos form new biomarker research collaboration

Ablynx signs Nanobodies collaboration agreement with Novartis

Novel agents for diabetes reported in recent patent literature

Recent patents describe novel agents for metabolic disorders

Novel therapeutics for neurological disorders reported in recent patent literature

Recent patent discloses novel therapeutic agents for ocular disorders

Continuous antiretroviral therapy found superior to episodic therapy

Data made available on 3G4, mouse equivalent of Tarvacin, in models of pancreatic cancer

alphaB-Crystallin proposed as a novel oncoprotein

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...